Pasar al contenido principal

DISEÑO DE POTENTES METALOFARMACOS Y SU SEGUIMIENTO EN EL NANOESPACIO INTRACELULAR

PID2020-117766GB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION IMDEA NANOCIENCIA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Flavin-conjugated Pt(IV) anticancer agents

  • Sánchez-Camacho, Juan
  • Infante-Tadeo, Sonia
  • Carrasco, Ana C.
  • Scoditti, Stefano
  • Martínez, Álvaro
  • Barroso-Bujans, Fabienne
  • Sicilia, Emilia
  • Pizarro, Ana M.
  • Salassa, Luca
In situ activation of Pt(IV) to Pt(II) species is a promising strategy to control the anticancer activity and overcome the off-target toxicity linked to classic platinum chemotherapeutic agents. Herein, we present the design and synthesis of two new asymmetric Pt(IV) derivatives of cisplatin and oxaliplatin (1·TARF and 2·TARF, respectively) bearing a covalently bonded 2′,3′,4′,5′-tetraacetylriboflavin moiety (TARF). 1H and 195Pt NMR spectroscopy shows that 1·TARF and 2·TARF can be effectively activated into toxic Pt(II) species, when incubated with nicotinamide adenine dinucleotide, sodium ascorbate, and glutathione in the dark and under light irradiation. Density functional theory studies of the dark Pt(IV)-to-Pt(II) conversion of 2·TARF indicate that the process involves first hydride transfer from the donor to the flavin moiety of the complex, followed by electron transfer to the Pt(IV) center. When administered to MDA-MB-231 breast cancer cells preincubated with nontoxic amounts of ascorbate, 2·TARF displays enhanced toxicity (between 1 and 2 orders of magnitude), suggesting that the generation of oxaliplatin can selectively be triggered by redox activation. Such an effect is not observed when 2 and TARF are coadministered under the same conditions, demonstrating that covalent binding of the flavin to the Pt complex is pivotal., We acknowledge financial support from the Spanish State Research Agency (Grants PID2019-109111RB-I00, RED2018-102471-T, FJC2021-047527-I, PRE2020-093560, and PID2020-117766GBI00), the Basque Government (Eusko Jaurlaritza Grants IT1254-19 and PIBA_2021_1_0034), the Diputación Foral de Gipuzkoa (RED 2021), and the Comunidad Autónoma de Madrid (Scholarship PEJD-2016/IND-2608). DIPC and IMDEA Nanociencia receive support from the “Severo Ochoa” Programme for Centres of Excellence in R&D (MINECO, Grants CEX2018-000867-S and CEX2020-001039-S, respectively). S.S. is grateful for financial support of the Calabria Region (Project POR Calabria, FSE/FESR 2014–2020)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Synthesis and characterization of a luminescent cyclic poly(ethylene oxide)-polypyridyl ruthenium complex

  • Aboudzadeh, M. Ali
  • Rodríguez-Fanjul, Vanessa
  • Terenzi, Alessio
  • González de San Román, Estíbaliz
  • Miranda, José Ignacio
  • Pizarro, Ana M.
  • Salassa, Luca
  • Barroso-Bujans, Fabienne
We report the synthesis of a macrocyclic poly(ethylene oxide) (PEO) connected by one [Ru(bpy)3]2+ unit (where bpy = 2,2'-bipyridine), a photoactive metal complex that provides photosensitivity and potential biomedical applications to this polymer structure. The PEO chain provides biocompatibility, water solubility, and topological play. The macrocycles were successfully synthesized by copper-free click cycloaddition between a bifunctional dibenzocyclooctyne (DBCO)-PEO precursor and 4,4'-diazido-2,2'-bipyridine, followed by complexation with [Ru(bpy)2Cl2]. The cyclic product accumulated efficiently in MCF7 cancer cells and exhibited a longer fluorescence lifetime than its linear analogue, likely due to differences in the accessibility of the ligand-centered/intraligand states of Ru polypyridyls in both topologies., We acknowledge financial support from MCIN/AEI/10.13039/501100011033 and “ERDF A way of making Europe” (PID2021-123438NB-I00), the MICINN (PID2020-117766GB-I00), the Basque Government (Eusko Jaurlaritza grants IT1566-22 and PIBA 2021-1-0034), and Diputación Foral de Gipuzkoa (RED 2021:ID44). DIPC and IMDEA Nanociencia received support from the “Severo Ochoa” Programme for Centres of Excellence in R&D (MINECO, Grants CEX2018-000867-S and CEX2020-001039-S, respectively). L.S. thanks the Spanish Multi-MetDrugs network (RED2018-102471-T) for fruitful discussion., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2018-000867-S and CEX2020-001039-S)., Peer reviewed